Piston

Piston Bio is a private clinical-stage biotechnology company developing therapeutics for cancer-associated neuroimmune and immuno-oncology pathways. Its lead program, PST-101, is an adenosine A2A receptor antagonist being advanced for cancer-related apathy, with FDA-aligned plans for a randomized Phase 2 study and an IND submission in 2026. Company materials also describe prior and parallel positioning of PST-101 in cancer cachexia and list additional earlier-stage assets including PST-102 and PST-103, aimed at motivation-related symptoms and tumor immune visibility. Piston Bio appears focused on oncology supportive care and tumor-directed mechanisms, using brain-penetrant small molecules and selected biologic approaches. The company is led by founder and CEO Walter Hong, MD, and is based in Morristown, New Jersey.